PUBLISHER: Grand View Research | PRODUCT CODE: 2067639
PUBLISHER: Grand View Research | PRODUCT CODE: 2067639
The global non-invasive cancer diagnostics market size was estimated at USD 80.87 billion in 2025 and is projected to reach USD 139.09 billion by 2033, growing at a CAGR of 7.1% from 2026 to 2033, due to the increasing prevalence of cancer, advancements in diagnostic technologies, and the growing initiatives undertaken by both public and private organizations to improve early detection and treatment. As the number of cancer cases continues to rise, there is a growing need for effective, accessible, and patient-friendly diagnostic methods.
Early detection plays a critical role in improving treatment outcomes and survival rates. Non-invasive diagnostic techniques enable healthcare providers to screen large populations and detect cancer at earlier stages without requiring complex or painful procedures. For example, according to the World Health Organization and the International Agency for Research on Cancer, the global burden of cancer is rising significantly.
In 2022, around 20 million new cancer cases and 9.7 million deaths were reported worldwide, with about 53.5 million people living within five years of a diagnosis. Cancer cases are expected to reach over 35 million by 2050, a 77% increase, mainly due to population aging, population growth, and risk factors such as tobacco use, alcohol consumption, obesity, and air pollution. As a result, the rising burden of cancer is increasing the demand for non-invasive diagnostic solutions across healthcare systems.
Global Non-Invasive Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-invasive cancer diagnostics market report based on product, technology, indication, end use, and region: